Does Vessel-sparing Surgery in Anterior Approach Total Hip Arthroplasty Change Clinical Outcome?
Launched by ZIEKENHUIS OOST-LIMBURG · Mar 5, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating a new surgical technique called vessel-sparing surgery during total hip arthroplasty (THA), which is a common surgery to replace a damaged hip joint. Traditionally, surgeons cut certain blood vessels during the operation, which may lead to pain in a muscle called the tensor fascia lata (TFL). The researchers want to see if avoiding this vessel damage can improve recovery and reduce tenderness in patients. They believe that this new method could be successful in about 60% of the patients.
To participate in this study, you need to be an adult who is scheduled for hip replacement surgery by specific surgeons and willing to provide consent. However, those with certain conditions, like severe nerve problems or previous hip surgeries, will not be eligible. If you join the study, you will undergo the new vessel-sparing technique, and the researchers will closely monitor your recovery compared to standard methods. This trial is currently looking for participants, and your involvement could help improve future hip surgeries for many patients.
Gender
ALL
Eligibility criteria
- • Inclusion criteria To be eligible to participate in this study, a subject must meet all criteria below;
- • Scheduled for THA by Dr. Frans-Jozef Vandeputte or Professor Dr. Kristoff Corten
- • Provide signed and dated informed consent
- • Males or females age \> 18 years
- • Exclusion criteria
- A potential subject who meets any of the following criteria will be excluded from participation in this study:
- • Neurological problems with sensorial and/or motoric disturbances (Multiple Sclerosis, Parkinson's disease, hemiplegia, ...)
- • Previous surgery of the ipsilateral hip
- • Ipsilateral neck of femur fracture
- • Previous contralateral THA
- • Significant hip deformity: Crowe type 3 and 4 dysplasia, Leg-Calvé-Perthes
- • Avascular necrosis of the femoral head
- • Participating in another study that may interfere with participation in this study
About Ziekenhuis Oost Limburg
Ziekenhuis Oost-Limburg (ZOL) is a leading healthcare institution in Belgium, dedicated to providing high-quality medical care and advancing clinical research. With a commitment to patient-centered practices, ZOL integrates innovative research within its healthcare services, fostering collaboration among multidisciplinary teams to enhance treatment outcomes. The hospital actively conducts clinical trials across various medical fields, aiming to contribute valuable insights to the scientific community and improve therapeutic options for patients. Through its robust research initiatives, ZOL strives to remain at the forefront of medical advancements while ensuring the highest standards of safety and ethical practices in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Genk, Limburg, Belgium
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported